Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 52-week open-label extension (OLE) study of Tradipitant for patients who had completed the phase II study (2301) in gastroparesis

Next Previous
Trial Profile

An 52-week open-label extension (OLE) study of Tradipitant for patients who had completed the phase II study (2301) in gastroparesis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tradipitant (Primary)
  • Indications Gastroparesis
  • Focus Therapeutic Use

Most Recent Events

  • 04 Mar 2019 New trial record
  • 13 Feb 2019 According to a Vanda Pharmaceuticals media release, the comapny is waiting for the further feedback from the FDA, till then no patients were ever enrolled in any study beyond 12 weeks.
  • 01 Sep 2018 According to a Vanda Pharmaceuticals media release, in Sep 2018, the company had submitted a new follow-on 52-week OLE protocol to the FDA, for patients who had completed the 2301 study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top